Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
199
Views
7
CrossRef citations to date
0
Altmetric
Original Research

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique

Hui-jun Wang1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Chun-yan Zhou1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Yan-ding Su1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Kai-feng Gou1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Xiao-nan Geng1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
&
Xiang-jun Qiu1 Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China;2 Functional Experiment Teaching Center, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7644-9598
ORCID Icon
Pages 4865-4873 | Published online: 30 Nov 2021

References

  • BauerS, GeorgeS, von MehrenM, HeinrichMC. Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Front Oncol. 2021;11:672500. doi:10.3389/fonc.2021.67250034322383
  • PatelSR, ReichardtP. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer. 2021;127(13):2187–2195. doi:10.1002/cncr.3363033974733
  • VallilasC, SarantisP, KyriazoglouA, et al. Gastrointestinal Stromal Tumors (GISTs): novel therapeutic strategies with immunotherapy and small molecules. Int J Mol Sci. 2021;22(2):493. doi:10.3390/ijms22020493
  • FaragS, SmithMJ, FotiadisN, ConstantinidouA, JonesRL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol. 2020;21(7):55. doi:10.1007/s11864-020-00754-832462367
  • BlayJY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 2011;37(5):373–384. doi:10.1016/j.ctrv.2010.11.00321195552
  • SmithBD, KaufmanMD, LuWP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738–751. doi:10.1016/j.ccell.2019.04.00631085175
  • Lostes-BardajiMJ, García-IllescasD, ValverdeC, SerranoC. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021;13:1–12. doi:10.1177/1758835920986498
  • ZalcbergJR. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Therap Adv Gastroenterol. 2021;14:1–12. doi:10.1177/17562848211008177
  • DhillonS. Ripretinib: first Approval. Drugs. 2020;80(11):1133–1138. doi:10.1007/s40265-020-01348-232578014
  • JankuF, Abdul RazakAR, ChiP, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a Phase I study of ripretinib. J Clin Oncol. 2020;38(28):3294–3303. doi:10.1200/JCO.20.0052232804590
  • FalconerN, RyanM, BadmanB, CarringtonC. Ripretinib for gastrointestinal stromal tumours. Aust Prescr. 2021;44:112. doi:10.18773/austprescr.2021.02534211252
  • BellmannR, SmuszkiewiczP. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737–779. doi:10.1007/s15010-017-1042-z28702763
  • YamaguchiY, AkiyoshiT, KawamuraG, et al. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metab Pharmacokinet. 2021;38:100384. doi:10.1016/j.dmpk.2021.10038433826998
  • CaiT, LiaoY, ChenZ, ZhuY, QiuX. The influence of different triazole antifungal agents on the pharmacokinetics of cyclophosphamide. Ann Pharmacother. 2020;54(7):676–683. doi:10.1177/106002801989689431893943
  • ZhouCJ, WangHJ, ZhouCY, LiCF, ZhuMJ, QiuXJ. Establishment and verification of UPLC-MS/MS technique for pharmacokinetic drug-drug interactions of selinexor with posaconazole in rats. Drug Des Devel Ther. 2021;15:1561–1568. doi:10.2147/DDDT.S303928
  • LiSL, ZhangY, ChengQS, XinJZ, DongZQ, QiuXJ. UPLC-MS/MS measurement of the effect of isavuconazole, itraconazole and fluconazole on the pharmacokinetics of selinexor in rats. Infect Drug Resist. 2020;13:3153–3161. doi:10.2147/IDR.S26983132982330
  • MoussetS, BuchheidtD, HeinzW, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93(1):13–32. doi:10.1007/s00277-013-1867-124026426
  • US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD, USA: US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research; 2018. Available from: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/bioanalyticalmethodvalidation-guidance-industry. Accessed August 10, 2018.
  • Chinese Pharmacopoeia Commission. Guidelines for Validation of Quantitative Analysis Methods for Biological Samples. Pharmacopoeia of the People’s Republic of China. China Medical Science and Technology Press; Vol. II, 2020:466–472.
  • TangC, NiuX, ShiL, ZhuH, LinG, XuRA. In vivo pharmacokinetic drug-drug interaction studies between fedratinib and antifungal agents based on a newly developed and validated UPLC/MS-MS method. Front Pharmacol. 2021;11:626897. doi:10.3389/fphar.2020.62689733613287
  • HuJ, SuXJ, SiHL, et al. Simultaneous determination of celecoxib, dezocine and dexmedetomidine in beagle plasma using UPLC-MS/MS method and the application in pharmacokinetics. Drug Des Devel Ther. 2021;15:2529–2541. doi:10.2147/DDDT.S314562

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.